New combo tackles tough lymphoma after other treatments fail

NCT ID NCT06192888

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether combining glofitamab (an IV drug) with lenalidomide (an oral drug) is a feasible treatment for people with mantle cell lymphoma that has returned or not responded to prior therapy, including a BTK inhibitor. The study enrolls 39 adults and focuses on whether participants can complete the first three treatment cycles without major delays. It is an early-stage trial, so the main goal is to assess feasibility, not yet to confirm effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Glofitamab (given by IV) and lenalidomide (taken by mouth)
What this could lead to: If this combination works, it could offer a new treatment option for people with mantle cell lymphoma that has come back after other therapies.
What could go wrong: This is a very early, small Phase 1 pilot study with only 39 participants. It is designed mainly to see if the treatment is feasible, not yet to prove it works. Side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA MCL

Contacts and locations

Locations

Dana Farber Cancer Institute (Data Collection and Specimen Analysis)

Boston, Massachusetts, 02115, United States
Mayo Clinic (Data Collection Only)

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Monmouth (Limited protocol activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (All protocol activities)

Rockville Centre, New York, 11553, United States
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited protocol activities)

Harrison, New York, 10604, United States
Washington University (Data Collection Only)

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.